PFC
CHRS icon

Phocas Financial Corp’s Coherus Oncology CHRS Stock Holding History

Phocas Financial Corp’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-293,538
Closed -$1.25M – 176
2023
Q2 		$1.25M Buy
293,538
+130,398
+80% +$769K 0.17% 128
2023
Q1 		$1.12M Buy
+163,140
New +$1.27M 0.16% 129
2022
Q3 		– Sell
-316,455
Closed -$2.29M – 203
2022
Q2 		$2.29M Sell
316,455
-67,555
-18% -$587K 0.34% 113
2022
Q1 		$4.96M Sell
384,010
-130,428
-25% -$1.66M 0.62% 72
2021
Q4 		$8.21M Buy
514,438
+9,502
+2% +$166K 1.05% 33
2021
Q3 		$8.11M Buy
504,936
+253,578
+101% +$3.72M 1.03% 29
2021
Q2 		$3.48M Buy
251,358
+49,730
+25% +$704K 0.44% 92
2021
Q1 		$2.95M Buy
201,628
+99,013
+96% +$1.68M 0.39% 103
2020
Q4 		$1.78M Sell
102,615
-20,847
-17% -$371K 0.27% 114
2020
Q3 		$2.26M Buy
123,462
+3,946
+3% +$73.4K 0.39% 108
2020
Q2 		$2.13M Sell
119,516
-10,343
-8% -$175K 0.38% 113
2020
Q1 		$2.11M Buy
129,859
+16,311
+14% +$301K 0.42% 101
2019
Q4 		$2.04M Buy
+113,548
New +$2.09M 0.25% 117

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Phocas Financial Corp's CHRS Position: Q3 2023 in Review

Phocas Financial Corp sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 293,538 shares — an estimated $1.25M sold.

Phocas Financial Corp first reported a position in CHRS in Q4 2019 and held it in 13 quarters. The position peaked at $8.21M in Q4 2021. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Phocas Financial Corp reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Phocas Financial Corp sold 293,538 Coherus Oncology shares in Q3 2023, an estimated $1.25M.
  • Phocas Financial Corp first reported a position in Coherus Oncology in Q4 2019 and held it in 13 quarters.
  • Phocas Financial Corp's Coherus Oncology position peaked at $8.21M in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Phocas Financial Corp's 13F filing for Q3 2023, filed 10 Oct 2023.